News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Receptos Provides Update on Progress of Lead Product Candidate RPC1063



6/5/2013 9:13:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, confirmed today that RPC1063, its selective sphingosine-1- phosphate 1 receptor (S1P1R) modulator, has successfully completed a study of the heart's electrical conduction system, known as a "thorough QT/QTc" (TQT) study. RPC1063 is currently being studied in randomized Phase 2 trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Receptos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES